LEI:
549300Q7EXQQH6KF7Z84
2 July
2024
RTW Biotech Opportunities
Ltd
New Investments in Mirador
Therapeutics & Santa Ana Bio
RTW Biotech Opportunities Ltd (the
"Company"), a London Stock Exchange-listed investment company
focused on identifying transformative assets with high growth
potential across the life sciences sector, is pleased to note
investments in new private portfolio companies, Mirador Therapeutics ("Mirador") and
Santa Ana Bio ("Santa
Ana").
The Company, alongside other
investment vehicles managed by RTW Investments, LP (the
"Investment Manager"),
participated in Mirador's Series A financing round that raised over
$400 million for its launch in March.
Mirador
Therapeutics is a next-generation precision medicine company
focused on immunology and inflammation. The company's Mirador360 TM
precision development engine leverages the latest advances in human
genetics and cutting-edge data science to rapidly advance new
precision medicines for patients living with chronic
immune-mediated inflammatory and fibrotic diseases.
Josh Kennedy-Smith,
Partner and Research Analyst at
the Investment Manager said, "We are thrilled to support Mirador
Therapeutics whose team we worked with when they led Prometheus
Biosciences through to its acquisition by Merck for $10.8 billion
in 2023. We have every confidence in their track record to
develop the next wave of precision medicines in immunology and
inflammation."
The Company, alongside other
investment vehicles managed by the Investment Manager, also
participated in Santa Ana's Series A financing round that raised
$168 million in May.
Santa
Ana Bio is a biotechnology company developing a pipeline of
innovative therapeutics and leveraging its multi-omics platform to
unlock the full potential of precision medicines. Santa Ana's
platform, based on transcriptomics and
proteomics, addresses the limitations of today's commercial
therapeutics.
Josh Kennedy-Smith said, "We're
excited to support Santa Ana as they advance their broad pipeline
of precision, next-generation antibodies for autoimmune diseases
into clinical development."
Commenting on recent activity,
Chief Investment Officer, Rod
Wong, said, "We are active again in
private investing and seeing a lot of opportunity. After a couple
of years of slower deployment as we focused on opportunities in the
public market, we now expect to head back to our normal pace of
about a dozen private deals per year, especially if the IPO window
continues to trend positively."
The full text of these portfolio
company announcements can be accessed here: https://santaanabio.com/.
https://miradortx.com/
For
Further Information
RTW
Investments, LP
|
+44
20 7959 6361
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
Charles Ryland
|
|
Henry Wilson
|
|
George Beale
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
Freddie Barnfield
|
|
Nathan Brown
|
|
Euan Brown
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
Edward Peel
|
|
Alex Penney
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
David Harris
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
14 8181 0100
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********